公开(公告)号：US20190117701A1

公开(公告)日：2019-04-25

申请号：US16096973

申请日：2017-04-27

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Eiko Uno ,  Masayo Yumoto ,  Mihoko Yoshino ,  Xuan Trung Ngo ,  Hiroyuki Nishida ,  Akiko Uetani

IPC: A61K35/28 ,  A61P29/00

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.

公开(公告)号：US11179420B2

公开(公告)日：2021-11-23

申请号：US16096973

申请日：2017-04-27

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi Ikeyama ,  Eiko Uno ,  Masayo Yumoto ,  Mihoko Yoshino ,  Xuan Trung Ngo ,  Hiroyuki Nishida ,  Akiko Uetani

IPC: C12N5/0775 ,  A61K35/28 ,  A61P29/00

Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.